News coverage about Esperion Therapeutics (NASDAQ:ESPR) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.7905466436182 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

NASDAQ:ESPR traded up $1.42 on Friday, hitting $48.09. The company’s stock had a trading volume of 24,295 shares, compared to its average volume of 919,604. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -6.84 and a beta of 2.29. Esperion Therapeutics has a one year low of $33.06 and a one year high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($0.01). During the same quarter in the previous year, the company posted ($1.92) earnings per share. equities research analysts forecast that Esperion Therapeutics will post -6.28 earnings per share for the current fiscal year.

Several research analysts recently commented on the company. BidaskClub cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 12th. ValuEngine cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, June 21st. Citigroup raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $57.00 to $75.00 in a research report on Friday. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Finally, UBS Group set a $75.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 16th. Two analysts have rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics presently has an average rating of “Buy” and an average price target of $82.04.

In other Esperion Therapeutics news, major shareholder Target N. V. Biotech acquired 130,000 shares of the company’s stock in a transaction on Monday, May 21st. The shares were purchased at an average price of $40.11 per share, for a total transaction of $5,214,300.00. Following the completion of the purchase, the insider now directly owns 2,872,964 shares of the company’s stock, valued at $115,234,586.04. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Target N. V. Biotech acquired 60,000 shares of the company’s stock in a transaction on Tuesday, June 5th. The stock was acquired at an average price of $38.47 per share, for a total transaction of $2,308,200.00. Following the purchase, the insider now directly owns 3,012,964 shares of the company’s stock, valued at $115,908,725.08. The disclosure for this purchase can be found here. Insiders acquired 460,000 shares of company stock worth $18,473,600 in the last 90 days. Corporate insiders own 14.50% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: How Important is Technical Analysis of Stocks

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.